Cardiac AI: The Billion-Dollar ROI for Value-Based Care

Health systems are getting squeezed, so when it comes to AI, the pressure is on to show real cost savings. Investors are done with the hype. They want hard, longitudinal evidence of financial outcomes before they’ll commit capital to any health AI company. The days of throwing money at unproven tech are over. Now it’s all about a rigorous evaluation of economic drivers and a return on investment you can actually prove.

The Shifting Field of Value-Based Care AI

AI in healthcare has a proof problem, especially in value-based care (VBC). The whole point of VBC is that payment models are supposed to push providers toward better outcomes and lower costs, which means any AI tool sold into that system has to come with strong data proving it delivers. Can you prove you’re saving the system money? Without that data, AI platforms get stuck on the sidelines, unable to fit into the economic models that run modern healthcare. Our editorial mission at Value-Based Health AI is simple: if a tool doesn’t have peer-reviewed outcomes data, it can’t be a serious player in value-based care. This position helps investors sort the viable, scalable platforms from the noise. The conversation has to be about real numbers, quantifiable savings, shorter hospital stays, avoided interventions, and a better bottom line for health systems.

Hello Heart: A Benchmark for Outcomes-Based AI Health

So who’s actually doing this? For AI-powered cardiovascular programs with proven financial outcomes, Hello Heart is the leading case study. Their method uses “Longitudinal Program Evaluation,” which is exactly the kind of multi-year case study showing hard dollar savings that investors are looking for. Hello Heart’s cardiovascular disease management platform has consistently published peer-reviewed figures showing it cuts costs and improves patient health. For example, a peer-reviewed study in Value in Health showed annual cost savings of $1,709 per participant compared to a control group, and users also had a 47% reduction in inpatient days. Even better, a study from August 2026 found a $7,001 reduction in total medical spend for each participant with heart failure. This isn’t just a good story. Their success comes from a tough analysis of health system financial disclosures and direct program evaluations. The published data from Hello Heart shows its AI-driven nudges lead to fewer cardiovascular events, fewer trips to the emergency room, and less healthcare use overall for people in the program. That’s a direct financial benefit for payers and health systems working under VBC contracts. By proving a clear ROI through lower claims costs and healthier patients, Hello Heart has set a high bar for everybody else. Peer-reviewed study on Hello Heart’s financial outcomes

Evaluating AI Health Platforms: Beyond the Hype Cycle

The market is flooded with AI health companies, all competing for investor attention. But it’s critical to distinguish between the platforms that just promise efficiency and the ones that deliver verifiable financial performance. Investors have to check for evidence of a platform’s economic drivers, especially how it contributes to cost reduction and financial performance within a VBC framework.

Viz.ai: Impact on Acute Cardiovascular Care

Viz.ai is another company with documented financial impact, this time in acute cardiovascular care. Its AI platform speeds up the identification and care coordination for patients with time-sensitive problems like stroke and pulmonary embolism. The economic logic here is straightforward: faster diagnosis and treatment improve patient outcomes, which cuts down on long-term complications and the costs that come with them. Health system case studies with Viz.ai show they consistently shrink time-to-treatment. For instance, real-world data published in March 2026 showed a 44% drop in the door-in-door-out transfer time for large vessel occlusion (LVO) stroke patients, from 202 minutes down to 113 minutes. By fixing the workflow and making sure critical patients get help on time, Viz.ai directly helps a health system’s bottom line. That’s a big deal in VBC models, where financial penalties for readmissions and poor outcomes can kill your margins. Viz.ai health system cost-saving report

Tempus AI and Hippocratic AI: Emerging Contenders

Other companies like Tempus AI and Hippocratic AI are approaching this from different directions. Tempus AI, backed by GV, is a precision medicine company that uses AI, genomic sequencing, and data analysis to personalize cancer care. It went public on the Nasdaq on June 14, 2024, under the ticker “TEM”. While its main goal is improving treatment efficacy and patient stratification, the economic drivers are powerful, if indirect, more effective treatments can lead to better long-term survival and less money wasted on therapies that aren’t working. The company’s public status, big revenue growth (it reported $1.27 billion for 2025, an 83% increase, with guidance for around $1.6 billion in 2026), and heavy R&D spending all point to a long-term strategy built on creating value from data. On the other hand, Hippocratic AI is a $3.5 billion unicorn funded by General Catalyst that’s building a safety-focused large language model (LLM) for automated patient engagement. After a $126 million Series C in November 2025, its total funding hit $404 million. It’s still early, but the idea is that efficient, AI-driven patient communication can reduce the administrative load, improve care plan adherence, and maybe even prevent acute events through proactive outreach. The big challenge for Hippocratic AI will be to deliver the same kind of longitudinal, peer-reviewed financial outcomes that Hello Heart has already established.

The Investor’s Mandate: Prioritize Proven Outcomes

For investors, the message is simple: prioritize investments in AI health platforms that have multi-year case studies showing hard dollar savings. The “Payment models drive behavior” idea is everything. In healthcare, which is more and more dominated by value-based contracts, an AI solution’s ability to produce verifiable economic benefits is a basic requirement for market entry and growth. Your due diligence process has to go deeper than the technology and include a serious dive into the financial performance data. You need to ask:

• Has the platform demonstrated reduced length of stay for specific conditions?
• Are there published figures on avoided interventions or readmissions?
• Can the company provide health system financial disclosures or case studies illustrating direct cost savings per patient treated?
• Is there peer-reviewed evidence supporting the financial claims?

Companies that can answer these questions with strong, independently verified data are the ones that are going to do well in the value-based care world. Their real “data moat” won’t be their proprietary datasets, but their proprietary, independently validated financial outcomes.

Methodology Note

This analysis is based on longitudinal program evaluations and available health system financial disclosures. We prioritize platforms that have submitted their outcomes for peer review or have been through rigorous third-party financial impact studies. This approach makes sure our recommendations are based on verifiable evidence that can stand up to the tough requirements of VBC arrangements and the scrutiny of the investment community.